BioSpace News Archive

The revolutionary advancements in the medical industry are rapidly transforming the healthcare scenario.

Heparin-induced thrombocytopenia is one of the most common side effects of heparin therapy. A number of thrombotic conditions need heparin therapy to reduce the risk of thrombosis.

Behcet’s disease is an inflammatory disorder that occurs in varied body parts. The most behcet’s disease-prone body parts are eyes, genital areas, stomach, joints, mouth, and the brain.

Guerbet and Bracco Imaging announced they have signed a global collaboration for Gadopiclenol, a next-generation magnetic resonance imaging contrast agent.

Moderna, a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the Ministry of Food and Drug Safety of Korea has issued a marketing authorization for Spikevax®, Moderna’s COVID-19 vaccine manufactured by Samsung Biologics, a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services.

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare disorders, announced its participation at upcoming investor and scientific conferences in January 2022.

GenSight Biologics reported topline efficacy and safety results at 2 years post-treatment administration in the REFLECT Phase III clinical trial with LUMEVOQ®.

Ultra-large volume wearable injectors are devices that are able to store high volume of drugs and are designed to deliver the drug subcutaneously over an extended period of time.

Alpha-1 antitrypsin (AAT) is a protein produced in the liver that circulates through blood. The alpha-1 antitrypsin protein primarily protects the body’s own tissues and cells from being damaged by activated immune response to foreign infection, autoimmune disorder, and other foreign particles.

The global pleural catheters market is foreseen to demonstrate substantial sales opportunities during the forecast period of 2020 to 2030.